Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.72 - $58.38
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.49M
Market Cap
$3.65B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.14B
Total Debt (Recent Filing)$2.47B
Price to Earnings (P/E)7.1
Beta1.50
Next Earnings
Jul 31, 2025EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.04
Shares Outstanding79,257,020
10 Day Avg. Volume2,251,192
30 Day Avg. Volume1,489,693
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)-3.80
Price to Sales (P/S)0.00
P/FCF Ratio-36.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$62.58Price Target Upside36.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePTC reported strong DMD revenues ahead of Street expectations, highlighting encouraging signs of brand loyalty despite the entrance of generics.
Regulatory ApprovalsManagement is confident about US approval for Sephience and is focusing on launch strategy in both the EU and US.
Strategic PartnershipsPTC signed an exclusive global license agreement with NVS for PTC518 in Huntington's disease in exchange for $1B upfront, up to $1.9B in development, regulatory and sales milestones, a 40/60 profit share in the U.S., and double-digit tiered royalties ex-U.S.
Bears Say
Market ChallengesThe core business was down 9% year-over-year, mainly as a result of the company’s DMD franchise.
Regulatory RisksThe company expects continued access and revenue generation from both new and existing DMD patients despite the recent EC adoption of the negative CHMP opinion.
---
Ownership Overview
1.31% Insiders
24.50% Mutual Funds
29.15% Other Institutional Investors
27.68% Public Companies and
Individual Investors
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $28.72 and its highest was $58.38 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $3.65B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Jul 31, 2025 which is in 73 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on May 06, 2025. The company reported $10.04 earnings per share for the quarter, beating the consensus estimate of -$1.008 by $11.048.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -1.04.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 79,257,020 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of $10.04 in its last earnings report, beating expectations of -$1.008. Following the earnings report the stock price went up 12.628%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
---
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.58 (36.01% Upside)
$62.58 (36.01% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $512.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.4%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.20%
12-Months-Change
Fundamentals
Return on Equity
33.08%
Trailing 12-Months
Asset Growth
48.38%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
---
PTCT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted a strong start to 2025, with significant progress in product launches and clinical trials. However, challenges remain with regulatory hurdles in Europe and ongoing competition from generics, balanced by strong cash reserves and strategic planning.Read More>---
PTCT Stock 12 Month Forecast
Average Price Target
$62.58
▲(36.01% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Rhythm Pharmaceuticals
―
Springworks Therapeutics
―
Avidity Biosciences
―
Arcellx Inc
―
---